Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Systematically Investigate Anti-Cancer Drug’s Modulation on T Cells in Tumor Microenvironment

Award Number: K99CA297120
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP
PERIOD OF PERFORMANCE START DATE: 08/01/2025
PERIOD OF PERFORMANCE END DATE: 07/31/2027

Group Awards By:

View Award Description

Systematically Investigate Anti-Cancer Drug’s Modulation on T Cells in Tumor Microenvironment - SUMMARY: Despite the transformative impact of immune checkpoint blockade (ICB) therapies in cancer treatment, the persistent challenge of low response rate and high risk of ICB resistance necessitates innovative approaches. Emerging studies acknowledge the immunomodulatory effects of conventional chemotherapies and small molecule inhibitors. However, due to the limited insight of interactions between drug treatment and tumor microenvironment, the synergy potential of most anti-cancer drugs with immunotherapy are not systematically evaluated. In our recent publication, we proposed a novel chemo-immunotherapy synergism prediction algorithm based on the post-treatment transcriptomic profiling of tumor cells and cancer patients. In this proposal, we seek to expand our approach to exploring the chemo-immunotherapy synergisms specifically through the lens of immune cell populations within tumor microenvironment. By comprehensively profiling pharmacologically or genetically perturbed T cells and analyzing their interactions with tumor cells, we seek to identify novel drug combinations that can overcome ICB resistance by modulating T cell activities. To achieve this goal, we have designed three specific aims: AIM I (K99) will conduct in silico screening of anti-cancer drugs that can impact T cell effector function, activation, stemness and proliferation; AIM II (K99-R00) will conduct single-cell CRISPR KO (scCRISPR-KO) screening of anti-cancer drug targets that can regulate T cell anti-tumor immunity; based on the Perturbed T Cell Signature Compendium (PerTCellS) built upon AIM I and II, AIM III (R00) will construct a T cell-centric ICB response signature and develop a novel synergy prediction algorithm to identify anti-cancer drugs that can boost ICB therapy through priming T cells. Our approach will provide a novel and comprehensive insight of interactions between anti-cancer drugs and T cell functionalities, which will facilitate the discovery and the repurposing of chemotherapy agents and small molecular inhibitors to enhance immunotherapy efficacy.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $121,857 )
2026	2026	UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION	4200 FIFTH AVENUE	PITTSBURGH	PA	15260	ALLEGHENY	USA	Cancer Research Manpower	000	2	7/16/2026	NON-COMPETING CONTINUATION	$121,857
														Subtotal = $121,857

Issue Date FY: 2025 ( Subtotal = $121,857 )
2025	2025	UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION	4200 FIFTH AVENUE	PITTSBURGH	PA	15260	ALLEGHENY	USA	Cancer Research Manpower	000	1	7/23/2025	NEW	$121,857
														Subtotal = $121,857

Grand Total All Awards = $243,714

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Systematically Investigate Anti-Cancer Drug’s Modulation on T Cells in Tumor Microenvironment

Award Number: K99CA297120

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP

PERIOD OF PERFORMANCE START DATE: 08/01/2025

PERIOD OF PERFORMANCE END DATE: 07/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer